Literature DB >> 23249795

Strategies to reduce treatment costs of peristomal skin complications.

Lina Martins1, Kathy Tavernelli, Wendy Sansom, Kirsten Dahl, Ineke Claessens, Terri Porrett, Birgitte Dissing Andersen.   

Abstract

Peristomal skin complications (PSCs) are common and troublesome and the consequences are substantial both for the patient and from a health-economic viewpoint. The purpose of this article is to demonstrate that early detection and treatment of PSCs, combined with the use of a correctly fitted and appropriate pouching system, can reduce treatment costs-in the UK, it is estimated to save £28.1m annually. A model for cost estimation of PSCs and a real-life global data set of people with stomas are used for the calculations. A high priority should be given to ensuring resources are available to provide education, guidance and assistance to people with a stoma. This would support increased awareness of the first signs of PSCs and enable self-management at an early stage.

Entities:  

Mesh:

Year:  2012        PMID: 23249795     DOI: 10.12968/bjon.2012.21.22.1312

Source DB:  PubMed          Journal:  Br J Nurs        ISSN: 0966-0461


  3 in total

1.  Design and validation of a "Peristomal Lesion Scale" for peristomal skin assessment.

Authors:  Giulia Menin; Gabriele Roveron; Maria Barbierato; Angela Peghetti; Renzo Zanotti
Journal:  Int Wound J       Date:  2018-12-13       Impact factor: 3.315

2.  Clinical and Economic Burden of Peristomal Skin Complications in Patients With Recent Ostomies.

Authors:  Charu Taneja; Debra Netsch; Bonnie Sue Rolstad; Gary Inglese; Lois Lamerato; Gerry Oster
Journal:  J Wound Ostomy Continence Nurs       Date:  2017 Jul/Aug       Impact factor: 1.741

3.  Cost-effectiveness of a Ceramide-Infused Skin Barrier Versus a Standard Barrier: Findings From a Long-Term Cost-effectiveness Analysis.

Authors:  Ariel Berger; Gary Inglese; George Skountrianos; Tonny Karlsmark; Mustafa Oguz
Journal:  J Wound Ostomy Continence Nurs       Date:  2018 Mar/Apr       Impact factor: 1.741

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.